ArticleFrontiers in pharmacology2026
The impact of caplacizumab in the treatment of immune thrombotic thrombocytopenic purpura. A retrospective monocentric cohort study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening disorder caused by severe ADAMTS13 deficiency, leading to microvascular platelet-rich thrombi, hemolysis, and organ damage, mainly involving brain, heart, kidneys, and intestines. Standard treatment includes plasma exchange (PEX) and immunosuppressants. Caplacizumab (CAPLA), an anti-von Willebrand factor nanobody, was recently introduced into clinical practice. Methods: We retrospectively analyzed 81 patients diagnosed with iTTP at our center from 1990 to 2024, accounting for 165 acute episodes requiring treatment. We compared outcomes between episodes treated with standard of care (SOC) and those with CAPLA, evaluating number of PEX sessions to platelet normalization, hospitalization length, CAPLA use, and disease stage (new onset vs. relapse). CAPLA was administered from episode onset until 30 days after PEX suspension. Results: Median age at first episode was 39.9 years (range 13-75), with 63% female patients. Over a median follow-up of 6.4 years, 47 patients (58%) experienced at least one relapse (range 1-7), all treated with PEX and corticosteroids. Of the 165 episodes, 39 (25.5%) were treated with CAPLA, 126 (74.5%) with SOC. Baseline characteristics were similar. Median PEX sessions were significantly lower in the CAPLA group (6 vs. 9.5; p < 0.0001), as were hospitalization days (8 vs. 13.5; p < 0.0001). Exacerbation after PEX occurred in 11 patients, more frequently in the CAPLA group (13% vs. 5%), associated with higher inhibitor levels (66 U/mL). Interestingly, patients who relapsed later had lower inhibitor levels at baseline (34 vs. 63 U/mL; p = 0.045) but longer hospital stays (12 vs. 10 days; p = 0.03), possibly due to less frequent CAPLA use (18% vs. 30%). Conclusion: Caplacizumab significantly reduces PEX sessions and hospitalization duration, leading to faster clinical response, regardless of disease stage or inhibitor level. However, its use may be linked to a higher rate of exacerbation, potentially due to earlier PEX discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.